| Aug 8 |
Replimune Group GAAP EPS of -$0.78 beats by $0.09
|
| Aug 8 |
Replimune Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update
|
| Jul 30 |
Replimune to Present at Two Upcoming Investor Conferences
|
| Jun 13 |
Replimune to raise ~$100M in private financing
|
| Jun 13 |
Replimune Announces $100 Million Private Placement Financing
|
| Jun 7 |
Replimune (REPL) Gains on Positive Data From Melanoma Study
|
| Jun 7 |
Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
|
| Jun 6 |
Sector Update: Health Care Stocks Higher in Late Afternoon Trading
|
| Jun 6 |
Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday?
|
| Jun 6 |
Replimune up 30% on results for RP1 combo in melanoma
|
